We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

47 hedge funds and large institutions have $593M invested in China Biologic Products Holdings, Inc. in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

88% more funds holding

Funds holding: 2547 (+22)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

46% more capital invested

Capital invested by funds: $407M → $593M (+$186M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.64M

Holders
47
Holders Change
+22
Holders Change %
+88%
% of All Funds
1.35%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
26
Increased
11
Reduced
7
Closed
4
Calls
Puts
$1.64M
Net Calls
-$1.64M
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
26
Jane Street
New York
$521K +$479K +11,720 New
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$483K +$444K +10,858 New
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$480K -$110K -2,700 -20%
Citadel Advisors
29
Citadel Advisors
Florida
$475K -$16.5K -405 -4%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$472K +$434K +10,614 New
LCM
31
Laurion Capital Management
New York
$374K +$343K +8,400 New
Point72 Asset Management
32
Point72 Asset Management
Connecticut
$356K +$327K +8,000 New
VKH
33
Virtu KCG Holdings
New York
$323K +$296K +7,253 New
PP
34
PDT Partners
New York
$298K +$274K +6,704 New
TAM
35
Telluride Asset Management
Minnesota
$209K +$192K +4,700 New
Geode Capital Management
36
Geode Capital Management
Massachusetts
$206K +$189K +4,633 New
RA
37
Royce & Associates
New York
$129K
PA
38
Perceptive Advisors
New York
$107K +$98K +2,400 New
TRCT
39
Tower Research Capital (TRC)
New York
$50K +$11.6K +284 +34%
Bank of America
40
Bank of America
North Carolina
$40K +$41 +1 +0.1%
Wells Fargo
41
Wells Fargo
California
$38K +$34.7K +850 New
BJ
42
BlackRock Japan
Japan
$25K +$22.5K +551 New
PCM
43
Prelude Capital Management
New York
$13K -$90.5K -2,216 -88%
OA
44
OFI Advisors
Pennsylvania
$11K +$1.55K +38 +17%
GSC
45
Ground Swell Capital
South Carolina
$9K +$8.17K +200 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$4K +$4.08K +100 New
WC
47
Wexford Capital
Florida
-$420K -12,100 Closed
NA
48
Navellier & Associates
Nevada
-$218K -6,273 Closed
U
49
UBS
Switzerland
-$40K -1,137 Closed
Deutsche Bank
50
Deutsche Bank
Germany
-$5K -167 Closed

CBPO Hedge Fund Activity: Q2 2014 in Review

47 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2014, worth a combined $593M — up 46% from $407M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBPO positions and 4 closed out — a net gain of 22 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Visium Asset Management, adding an estimated $14M. The largest seller was HSBC Holdings, cutting an estimated $2.21M.

  • 47 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2014, up from 25 in Q1 2014.
  • Funds reported $593M of China Biologic Products Holdings, Inc. stock for Q2 2014, up 46% quarter-over-quarter.
  • 26 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2014 and 4 closed out, a net change of +22 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q2 2014 was Visium Asset Management, an estimated $14M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q2 2014 was HSBC Holdings, an estimated $2.21M sold.

Based on aggregated 13F filings for Q2 2014.